Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Approximately 6.2% of the company’s stock are short sold. Based on an average daily volume of 179,700 shares, the short-interest ratio is currently 13.6 days.

Insider Buying and Selling at Aura Biosciences

In other Aura Biosciences news, CFO Julie B. Feder sold 6,609 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total value of $50,492.76. Following the transaction, the chief financial officer now directly owns 62,991 shares of the company’s stock, valued at approximately $481,251.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Los Pinos Elisabet De sold 15,853 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $7.64, for a total transaction of $121,116.92. Following the sale, the insider now directly owns 161,438 shares of the company’s stock, valued at approximately $1,233,386.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Julie B. Feder sold 6,609 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total value of $50,492.76. Following the sale, the chief financial officer now directly owns 62,991 shares in the company, valued at $481,251.24. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in AURA. Royal Bank of Canada raised its position in shares of Aura Biosciences by 192.2% during the 2nd quarter. Royal Bank of Canada now owns 3,866 shares of the company’s stock valued at $47,000 after acquiring an additional 2,543 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Aura Biosciences by 257.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,604 shares of the company’s stock valued at $59,000 after acquiring an additional 4,758 shares in the last quarter. California State Teachers Retirement System grew its stake in Aura Biosciences by 20.2% during the 1st quarter. California State Teachers Retirement System now owns 8,794 shares of the company’s stock worth $82,000 after buying an additional 1,478 shares during the last quarter. Trexquant Investment LP bought a new position in Aura Biosciences during the 3rd quarter worth $95,000. Finally, Susquehanna International Group LLP bought a new position in Aura Biosciences during the 1st quarter worth $96,000. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 3.8 %

AURA stock opened at $7.26 on Wednesday. The firm has a market cap of $359.37 million, a P/E ratio of -3.78 and a beta of 0.36. Aura Biosciences has a 12-month low of $5.99 and a 12-month high of $13.50. The stock’s 50 day simple moving average is $8.17 and its 200 day simple moving average is $8.32.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.